NCT01005797

Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers

A Phase I Safety and Tolerability Study of LBH589 in Combination With Sorafenib in Patients With Advanced Renal Cell Carcinoma, Soft Tissue Sarcoma, and Non-small Cell Lung Carcinoma (NSCLC) of Non-squamous Histologies.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Medical University of South Carolina · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if a new investigational drug called Panobinostat is safe, tolerable and to obtain an initial assessment of efficacy, when given in combination with Sorafenib for the treatment of certain types of lung cancer, kidney cancer and soft tissue sarcoma.

Conditions

• Renal Cancer
• Non Small Cell Lung Cancer (NSCLC)
• Soft Tissue Sarcoma

Interventions

Type	Name	Description
DRUG	Panobinostat (LBH589), Sorafenib	Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.

Timeline

• Start date: 2009-11-01
• Primary completion: 2014-03-01
• Completion: 2017-01-01
• First posted: 2009-11-02
• Last updated: 2017-03-03

Locations

1 site across 1 country: United States